Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin vs Avastin + Triamcinolone for CRVO
NCT00370630Phase 2Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevacizumab and triamcinolone acetonide in central retinal vein occlusion (CRVO), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Best corrected visual acuity at 24 weeks. Status: unknown.
02
Drugs
bevacizumabtriamcinolone acetonide
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT00370630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00370630.